Fast enrollment of mobile devices into the IT environment

Rolling out mobile devices with mobile device management was once a challenge. User’s couldn’t always set up their mobile devices alone and IT admins had other priorities. Fast Enrollment is the solution.

YouTube

By loading the video, you agree to YouTube’s privacy policy.
Learn more

Load video

Cortado has developed “Fast Enrollment” and it couldn’t be any easier to use.

The MDM enrollment process was once complicated, but with Fast Enrollment, shown in the following video, you can see that this is no longer the case.

Enrollment with QR Codes

With Fast Enrollment, mobile devices are instantly integrated into the existing IT infrastructure by simply scanning a QR code. Users receive their devices fully preconfigured, including all certificates, the MDM profile, and the Cortado client.

Time-consuming helpdesk calls while setting up devices are no longer an issue. Via the Management Console, the administrator assigns the users their device and the relevant rights.

Fast Enrollment is done via an automatically generated QR code which ensures quick and easy deployment. When the administrator scans this code, all certificates, the MDM profile and the Cortado client are installed on the mobile device.

One of the best features of using this fast enrollment method, is that with relatively few clicks you can get a whole range of devices set-up quickly. Each device can then be distributed fully preconfigured to the user, and the advantages are obvious: Users no longer need to be supervised when setting up devices.

Use Cortado MDM solutions, to get mobile devices ready for enterprise use.

See for Yourself with our Free Trial

Make sure to visit our webpage, if you haven’t already done so, to secure yourself a free trial of all Cortado MDM features. The entire range of Cortado MDM solutions and features can be found here. There is no obligation to pay and no credit card needs to be linked to the account. Just try it out and decide for yourself!

Start Free Trial

Comments are closed.